search
Back to results

Clinical Investigation of the eyeWatch Glaucoma Drainage Device

Primary Purpose

Open Angle Glaucoma

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
eyeWatch system
Sponsored by
Rheon Medical SA
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Open Angle Glaucoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patient must be 18 years of age or older.
  • Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory POAG or PEXG after previous failed filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma.
  • Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study.
  • Patient condition is indicated for primary and secondary filtration surgery.
  • Presence of elevated intraocular pressure defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery.
  • Optic neuropathy is exclusively attributed to glaucoma.
  • Patient agreed to sign the written inform consent prior to entering into the investigation.
  • Patient is able and willing to complete post-operative follow-up requirements.

Exclusion Criteria:

  • Diagnosis of neovascular glaucoma, congenital glaucoma.
  • History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery.
  • Proliferative or severe non-proliferative retinopathy in either eye.
  • Congenital anomaly of the anterior chamber angle in the study eye.
  • Optic neuropathy other than glaucoma in the study eye.
  • Patient with retinal vein occlusion in the study eye.
  • Patient with retinal artery occlusion in the study eye.
  • Patient with corneal opacifications, endotheliopathy, or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye.
  • Patient with a history of severe eye trauma in the study eye.
  • Patient with ocular malformations such as microphthalmia in the study eye.
  • Patient with concurrent inflammatory/infective eye disorder in the study eye.
  • Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants.
  • Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation.
  • Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)

Sites / Locations

  • St. Thomas' Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

eyeWatch device

Arm Description

Outcomes

Primary Outcome Measures

Number and type of serious adverse device events
Demonstration of safety. The number and type of serious adverse device event per patient will be measured. Results of biomicroscopy, gonioscopy, pachymetry visual field and endothelial count will be compared to baseline.
Effectiveness in reducing the intraocular pressure
Demonstration of the performance. The intraocular pressure (IOP in mmHg) will be measured at different time points to show the effective reduction compared to baseline. IOP reduced by ≥ 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 1 month (included)

Secondary Outcome Measures

Full Information

First Posted
July 1, 2017
Last Updated
October 26, 2021
Sponsor
Rheon Medical SA
search

1. Study Identification

Unique Protocol Identification Number
NCT03210571
Brief Title
Clinical Investigation of the eyeWatch Glaucoma Drainage Device
Official Title
Clinical Investigation of the eyeWatch Glaucoma Drainage Device
Study Type
Interventional

2. Study Status

Record Verification Date
October 2021
Overall Recruitment Status
Completed
Study Start Date
May 1, 2018 (Actual)
Primary Completion Date
October 27, 2020 (Actual)
Study Completion Date
October 27, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Rheon Medical SA

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
This study aims to test a new medical device, called the eyeWatch, used in filtering surgery for the treatment of glaucoma. This medical device has the following property: it allows better control of intraocular pressure in the initial postoperative phase by adjusting aqueous flow going through the device. The target criteria for the study are defined as: keeping intraocular pressure in target range; reducing the number of anti-glaucoma drugs; evaluating the number and type of postoperative complications. So far, this device has been already tested on 20 patients in Switzerland.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Open Angle Glaucoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
eyeWatch device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
eyeWatch system
Other Intervention Name(s)
Adjustable glaucoma drainage device (AGDD)
Intervention Description
The eyeWatch device is composed of an AGDD, a control unit and a draining plate
Primary Outcome Measure Information:
Title
Number and type of serious adverse device events
Description
Demonstration of safety. The number and type of serious adverse device event per patient will be measured. Results of biomicroscopy, gonioscopy, pachymetry visual field and endothelial count will be compared to baseline.
Time Frame
Follow-up: day 1, Week 1, week 2, month 1, month 2, month 3, month 6, month 12 compared to baseline
Title
Effectiveness in reducing the intraocular pressure
Description
Demonstration of the performance. The intraocular pressure (IOP in mmHg) will be measured at different time points to show the effective reduction compared to baseline. IOP reduced by ≥ 20% or IOP < 21 mmHg, and no IOP < 5 mmHg on two consecutive visits after 1 month (included)
Time Frame
Follow-up: day 1, Week 1, week 2, month 1, month 2, month 3, month 6, month 12 compared to baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient must be 18 years of age or older. Patient shall suffer from primary open angle glaucoma, pseudo-exfoliative glaucoma, or refractory POAG or PEXG after previous failed filtering surgery, in the study eye. Diagnosis is based on glaucomatous optic neuropathy, Shaffer angle greater than 2 as seen on gonioscopy, and visual field defect attributed to glaucoma. Eye to be treated shall be phakic or pseudophakic with no other active ocular disease or disorder except for incipiens cataract. Prior ophthalmic surgery in the study eye shall have been performed more than 3 months before enrollment in this study. Patient condition is indicated for primary and secondary filtration surgery. Presence of elevated intraocular pressure defined as an intraocular corrected pressure (IOP) > 20 mmHg in the study eye, under maximally tolerated medications. The IOP level shall be obtained on 2 consecutive measurements (not taken on the same day) prior to surgery. Optic neuropathy is exclusively attributed to glaucoma. Patient agreed to sign the written inform consent prior to entering into the investigation. Patient is able and willing to complete post-operative follow-up requirements. Exclusion Criteria: Diagnosis of neovascular glaucoma, congenital glaucoma. History of previous intraocular surgery in the study eye referring to but not limited to extraocular muscles (strabismus), corneal transplant, retinal surgery. Proliferative or severe non-proliferative retinopathy in either eye. Congenital anomaly of the anterior chamber angle in the study eye. Optic neuropathy other than glaucoma in the study eye. Patient with retinal vein occlusion in the study eye. Patient with retinal artery occlusion in the study eye. Patient with corneal opacifications, endotheliopathy, or irregularities that may interfere with the optic nerve evaluation or the IOP measurements in the study eye. Patient with a history of severe eye trauma in the study eye. Patient with ocular malformations such as microphthalmia in the study eye. Patient with concurrent inflammatory/infective eye disorder in the study eye. Patient with severe systemic disease or disabling conditions such as chronic renal failure, post organ transplants. Patient participating in another clinical trial or having participated in another clinical trial less than 3 months prior to entering into the investigation. Patient is pregnant, breast-feeding or unable to make the decision to participate in a clinical investigation (e.g. mentally ill person, mentally handicapped person)
Facility Information:
Facility Name
St. Thomas' Hospital
City
London
ZIP/Postal Code
SE1 7EH
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan
Citations:
PubMed Identifier
24557347
Citation
Villamarin A, Roy S, Bigler S, Stergiopulos N. A new adjustable glaucoma drainage device. Invest Ophthalmol Vis Sci. 2014 Mar 25;55(3):1848-52. doi: 10.1167/iovs.13-12626.
Results Reference
background

Learn more about this trial

Clinical Investigation of the eyeWatch Glaucoma Drainage Device

We'll reach out to this number within 24 hrs